
AZINUS-200 Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
AZINUS-200
Azithromycin 200mg Oral Suspension
AZINUS-200 is a broad-spectrum bactericidal antimicrobial agent exhibiting enhanced pharmacokinetic tissue penetration against susceptible gram-positive and gram-negative pathogens.
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
Inhibits bacterial DNA gyrase (type II topoisomerase) and topoisomerase IV enzymes required for bacterial DNA replication, transcription, and repair.
Adult: One dose once or twice daily depending on infectious severity. Complete full course to prevent antimicrobial resistance.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store below 25°C. Do not freeze. Keep container tightly closed.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
AZINUS-200 features Azithromycin 200mg Oral Suspension prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Customer & Clinical Reviews
Real feedback from registered physicians, stockists, PCD franchise partners, and verified buyers.
Based on 1 verified review
Evaluated across our institutional for AZINUS-200
AZINUS-200 has been evaluated across our institutional healthcare network, leading to verified clinical improvement without secondary complaints or nausea. The pack design is aesthetically modern with distinct therapeutic labeling that eliminates dispensing errors. Both consulting doctors and stocking pharmacists rate this formulation among the best in its class.
Questions Regarding AZINUS-200
What is the therapeutic indication and composition of AZINUS-200?
AZINUS-200 contains Azithromycin 200mg Oral Suspension indicated for Lower Respiratory Tract Infections as formulated by Sygnus Biotech.
What packaging presentations are available for AZINUS-200?
AZINUS-200 is supplied in tamper-evident 100ml / 200ml PET Bottle with Graduated Measuring Cap, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for AZINUS-200?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for AZINUS-200 along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
AZINUS-200 is categorized as Schedule H with an introductory PCD franchise MOQ of 100 units per batch.





